ELMWOOD PARK, N.J.,
April 1, 2021 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), today announced a COVID-19 testing agreement for
players and staff, stadium employees and league staff for the 2021
Major League Baseball (MLB) season.
BioReference announced a COVID-19 testing agreement for the 2021
Major League Baseball (MLB) season.
Under the agreement with MLB, BioReference will provide on-site
rapid PCR point-of-care COVID-19 testing to all 30 MLB teams,
leveraging Mesa Biotech's Accula System. Testing begins today,
April 1, 2021 coinciding with Opening
Day and will continue throughout the season.
"With this announcement, BioReference is now supporting all five
major professional men's sports leagues in the United States in safely moving forward
with their seasons," said Jon R.
Cohen, M.D., Executive Chairman of BioReference
Laboratories. "BioReference is proud to provide COVID-19
solutions to help ensure the return to a safe, full MLB season in
2021. MLB and our other sports league clients have continued to
demonstrate exemplary commitment to the health and safety of their
players, employees, and stadium staff throughout the pandemic."
"We're excited to be partnering with BioReference and look
forward to their help in bringing baseball back in 2021. Safety is
our top priority, and we're committed to making sure that our Clubs
across the country are able to play a full season and that everyone
involved stays healthy," said Jon
Coyles, Vice President of Drug, Health and Safety Programs
at the Office of the Commissioner of Baseball. "We're ready for
a great season. Play ball!"
To learn more about BioReference's COVID-19 testing, please
visit: https://www.bioreference.com/coronavirus/.
About BioReference Laboratories, Inc.
BioReference Laboratories, Inc., is one of the largest full service
specialty laboratories in the United
States that gives healthcare providers and patients the
power to make confident healthcare decisions. With a focus on
genetics, oncology, urology and women's health, BioReference offers
comprehensive test solutions and unparalleled expertise based on a
40 year legacy of proven science. The company is in-network with
the largest health plans in the United
States, serves approximately 19 million patients annually,
operates a network of 11 laboratory locations, and is backed by a
medical staff of more than 300 M.D.,
D.O., Ph.D., genetic counselors and other professional clinical and
scientific personnel. With a national footprint and niche market
experience, BioReference provides credible and innovative solutions
that meet the needs of employers, governmental agencies,
educational systems, hospitals and health systems, correctional
institutions, sports leagues, travel and leisure industries, and
retail markets. BioReference provides industry-leading custom
solutions for COVID-19, including point-of-care testing and
large-scale screening programs.
https://www.bioreference.com/
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company
that seeks to establish industry-leading positions in large,
rapidly growing markets by leveraging its discovery, development,
and commercialization expertise and novel and proprietary
technologies. For more information,
visit www.opko.com.
Contacts:
Media Inquiries
Hillary Titus, 201-406-9968
htitus@bioreference.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bioreference-laboratories-expands-its-major-league-sports-relationships-with-addition-of-major-league-baseball-301260267.html
SOURCE BioReference Laboratories, Inc